INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Buys 7,700 Shares

INmune Bio, Inc. (NASDAQ:INMBGet Rating) CFO David J. Moss bought 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The stock was purchased at an average cost of $6.27 per share, with a total value of $48,279.00. Following the completion of the transaction, the chief financial officer now directly owns 1,244,651 shares in the company, valued at $7,803,961.77. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of INMB opened at $6.80 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 23.89 and a quick ratio of 23.89. The stock has a 50 day moving average price of $7.64 and a two-hundred day moving average price of $9.22. INmune Bio, Inc. has a 52 week low of $4.63 and a 52 week high of $30.37.

INmune Bio (NASDAQ:INMBGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.21. During the same period in the prior year, the business earned ($0.32) earnings per share. On average, equities analysts anticipate that INmune Bio, Inc. will post -2.05 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of INmune Bio by 8.3% in the first quarter. Vanguard Group Inc. now owns 553,638 shares of the company’s stock valued at $4,661,000 after acquiring an additional 42,609 shares in the last quarter. ACT Capital L.L.C. purchased a new position in INmune Bio in the third quarter valued at approximately $5,341,000. BlackRock Inc. lifted its stake in INmune Bio by 59.3% in the fourth quarter. BlackRock Inc. now owns 233,265 shares of the company’s stock valued at $2,379,000 after purchasing an additional 86,836 shares during the last quarter. Millennium Management LLC lifted its stake in INmune Bio by 22.0% in the fourth quarter. Millennium Management LLC now owns 150,680 shares of the company’s stock valued at $1,537,000 after purchasing an additional 27,169 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in INmune Bio by 90.2% in the third quarter. Royal Bank of Canada now owns 126,411 shares of the company’s stock valued at $2,455,000 after purchasing an additional 59,953 shares during the last quarter. 13.91% of the stock is owned by institutional investors.

A number of analysts recently commented on the company. Zacks Investment Research raised INmune Bio from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research report on Friday, May 13th. B. Riley lowered INmune Bio from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $14.00 to $7.00 in a report on Tuesday, May 24th. Maxim Group started coverage on INmune Bio in a report on Friday, May 6th. They set a “buy” rating and a $22.00 price objective for the company. Finally, BTIG Research decreased their price objective on INmune Bio from $31.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, May 24th.

INmune Bio Company Profile (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

See Also

Insider Buying and Selling by Quarter for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.